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ABSTRACT 
Objective: A number of structural and functional mechanisms have been identified in the pathogenesis of impaired wound healing in diabetes. 
Diabetes promotes endothelial dysfunction as evidenced by decreased nitric oxide (NO) production. NO deficiency and resultant impaired 
angiogenesis have been implicated in impaired wound healing in diabetes. The objective of this study was to evaluate the effects of amlodipine and 
enalapril on wound healing in streptozotocin induced diabetic rats based on previous observations that amlodipine increases NO bioavailability and 
enalapril promote angiogenesis.  
Methods: Four groups for each wound model (n=6 in each group; total 8 groups) were used and served as diabetic control, active control 
(glibenclamide), amlodipine, and enalapril groups. Wound closure rate and re-epithelialization were studied in the excision wounds. Incision 
wounds were studied for wound breaking strength while dead space wounds were studied for granulation tissue weight, hydroxyproline content, 
and histological changes in granulation tissue.  
Results: Amlodipine and enalapril significantly (P<0.05) increased re-epithelialization in excision wound model. Amlodipine significantly improved 
incision wound breaking strength while enalapril increased granulation tissue formation. None of the study agents had a significant effect on wound 
granulation tissue histology.  
Conclusion: Amlodipine and enalapril enhance the re-epithelialization in the diabetic wound. Choosing amlodipine or enalapril as antihypertensive 
in diabetic patients may help to improve impaired wound healing in these patients. Further human trials are needed to demonstrate similar benefits 
in diabetic patients with wounds. 
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INTRODUCTION 
The wound healing is a highly dynamic and complex process of an 
integrated series of cellular, physiological and biochemical events 
leading to the re-establishment of structural integrity and functional 
restoration of the injured tissue. Impaired wound healing in diabetes 
mellitus (DM) accounts for high morbidity and health care cost [1, 
2]. Micro and macrovascular abnormality, impaired epithet–
lialization, and reduced angiogenesis have been described as some 
of the important causative mechanisms for impaired wound healing 
in diabetes [3]. Nitric oxide (NO) is one of the major factors 
regulated by endothelium that maintains vascular homeostasis [4]. 
Diabetes-related endothelial dysfunction and resultant decreased 
NO production/bioactivity [5] could plausibly play an important role 
in impaired wound healing in diabetes. Moreover, it has been 
demonstrated that impaired wound healing in diabetes is 
attributable to reduced wound NO synthesis [6]. In addition, topical 
application of NO donor has been shown to improve re-
epithelialization in wound healing [7]. A third-generation calcium-
channel blocker, amlodipine has been observed to enhance endothelial 
NO bioavailability by increasing NO production and prolonging NO 
half-life through its antioxidant property [8]. Formation of new blood 
vessels (angiogenesis) in wound bed is necessary to sustain the newly 
formed granulation tissue. Diabetes significantly hampers 
angiogenesis and thereby wound healing [9]. Angiogenesis stimulating 
property of angiotensin-converting enzyme (ACE) inhibitors has been 
proved previously and patented [10-12]. 
As amlodipine and enalapril were previously studied for their 
wound healing activities in dexamethasone suppressed and normal 
wound respectively [13-15], we designed present study to evaluate 
effects of amlodipine, and enalapril on diabetic wound healing in 
Wistar albino rats.  
MATERIALS AND METHODS 
This study was approved by institutional animal ethics committee 
(IAEC), government medical college, Bhavnagar (GMCB), Gujarat 
(India). (Approval no.–26/2012; Pharmacology no.–24/2012.) Adult, 
Wistar albino rats of either sex (weighing 200–350 gm) were 
procured from the central animal house, GMCB. They were 
acclimatized to animal holding room/laboratory environment and 
placed in individual polypropylene cages. They were maintained on 
normal food and water ad libitum, under controlled room 
temperature (25 °C±2 °C, 60–70 % humidity) and 12–12 h light-dark 
cycle. 
Streptozotocin (STZ)-induced diabetes 
A single dose of streptozotocin 50 mg/kg (Alfa Aesar, A Johnson 
Matthey Company, MA/USA, CAS: 18883-66-4) was given by 
intraperitoneal route to produce diabetes. [7] Four days after, 
random blood sugar (RBS) was measured from a blood drop, drawn 
from the tail vein, using glucometer (Accu–Chek Go, Roche 
Diagnostic, Germany). The rats showing RBS>300 mg/dl were used 
in subsequent experiments. Intermittent-acting neutral protamine 
hagedorn (NPH) insulin (5 IU/kg; Wosulin, Wockhardt Limited, 
Aurangabad, India) was given subcutaneously, once a day, to 
maintain RBS between 250–350 mg/dl.  
Experimental design, and wound models 
Forty-eight diabetic Wistar albino rats were divided into eight groups 
(n=6 in each group). Group I (Diabetic control), Group II 
(Glibenclamide–active control), Group III (Amlodipine), and Group IV 
(Enalapril) served as the excision wound groups. Group 1 received 1 
ml distilled water, group 2 received 0.5 mg/kg glibenclamide (SIGMA 
Life science, New Delhi, India), group 3 received 3 mg/kg amlodipine, 
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and group 4 received 15 mg/kg enalapril (Cadila Pharmaceuticals Pvt. 
Ltd., Dholka, Ahmedabad, Gujarat, India) orally daily till complete 
healing of the excision wounds. Group V (Diabetic control), Group VI 
(Glibenclamide–active control), Group VII (Amlodipine), and Group 
VIII (Enalapril) served as incision and dead space wound groups and 
received the same doses of respective treatment agent as described 
above for 11 d. All the wounds were inflicted under aseptic 
precautions and anesthesia induced by ketamine (75 mg/kg) and 
xylazine (10 mg/kg) administered intraperitoneally.  
Excision wound 
A full-thickness circular skin patch (measuring approximately 500 
mm2) was excised from the nape of the neck to produce excision 
wound [16]. Wound contraction and re-epithelialization were 
evaluated by tracing wound margin on a transparent plastic sheet. 
Wound area was measured soon after wounding and 3, 7, and 11 d 
later without scab removal. Re-epithelialization was measured on 11th 
day of wounding as by 11th day scabs fell off the wound, and 
epithelium was visible. The plastic sheet was scanned, and the wound 
area was measured using a UTHSCA image analyzer (version 3.00, The 
University of Texas Health Science Center, San Antanio, USA). Wound 
closure rate was calculated using the formula below [7]:  
Wound closure rate (%) = Areaday0−Areadayn
Areaday0
 × 100 
Where Areaday0=initial wound area at day 0, 
Areadayn=area on nth post wounding day 
The wound re-epithelialization was calculated using the formula 
mentioned below:  
Re−epithelialization (%) on 11th 
 
Total wound area (%) − Wound area not covered with epidermis (%) 
Re-sutured incision and dead space wound 
day =  
Two 5 cm long, para-vertebral, full-thickness incisions were made 
on either side of the vertebral column and sutured [17]. In the same 
rats, the dead space wounds were created by inserting and suturing 
sterile grass pith (measuring 2.5 cm×0.3 cm) in the loose areolar 
tissue of the groins on either side. A sterile cotton pellet (weighing 
10 mg) was inserted and sutured in both the axillary regions. The 
sutures were removed on 7th day of wounding in incision wounds 
and on 11th day in dead space wounds. The incision wound breaking 
strength was measured on 11th post wounding day by constant 
water flow technique described by Lee, under anesthesia [18]. After 
measuring wound breaking strength, the rats were sacrificed with a 
high dose of ketamine and xylazine, and the granulation tissue 
formed on grass piths were harvested. This granulation tissue were 
subjected to hydroxyproline estimation and histological examination 
[19]. The hydroxyproline content was expressed as μg/100 mg of 
granulation tissue. The axillary cotton pellets were excised and dried 
overnight at 60o
Statistical analysis 
C in the hot air oven. The weight of dried granulation 
tissue with cotton pallet was measured and expressed as mg/100 gm 
body weight [20]. A pathologist, semi-quantitatively, analyzed the 
haematoxylin and eosine (H & E) stained sections of granulation tissues 
and graded (grade 1–4) them for the presence of polymorphonuclear 
cells, macrophages, fibroblasts, and neoangiogenesis [21]. 
Statistical analysis was done by using Graphpad instat demo version 
number 3.0. The data were expressed as mean±standard error of 
mean (SEM). One way analysis of variance (ANOVA) followed by 
Tukey-Kramer test for parametric variables and Kruskal-Wallis 
followed by Dunn’s multiple comparison tests for non-parametric 
variables were used to compare mean differences between different 
groups. P<0.05 was considered statistically significant. 
RESULTS 
Excision wound 
The percentages of re-epithelialization on 11th post wounding day 
were significantly higher in amlodipine, and enalapril-treated 
groups as compared to control, and glibenclamide groups (table 1; 
P<0.05). There was no significant difference in wound closure rates 
among the groups (table 1). Wound closure was initially rapid 
because of wound contraction followed by slow closure through re-
epithelialization (fig. 1). The dynamics of wound closure in different 
groups are illustrated in the wound healing curve (fig. 2). Initially, 
the wound healing was slow in amlodipine and enalapril group 
followed by relatively rapid healing through re-epithelialization as 
compared to glibenclamide group (table 1).  
 
Table 1: Effect of amlodipine and enalapril on excision wound model 
S. No. Groups (n=6) Wound closure (%) Re-epithelialization (%) 11th day 
3rd 7 Day th 11 Day th Day 
1 Diabetic control 15.3±1.4 37.3±3.8 56.3±3.4 56.01±2.5 
2 Glibenclamide 15.7±1.2 46.7±1.8 57.6±2.5 63.2±1.8 
3 Amlodipine 15.3±2.1 41.9±3.9 69.6±5.8 78.6±1.5*
4 
# 
Enalapril 22.4±1.2 41.9±3.0 69.7±2.6 79.1±2.7*# 
n=6 in each group, values are represented as mean±SEM, *P<0.05 as compared to diabetic control and #
 
Re-sutured incision and dead space wound 
P<0.05 as compared to glibenclamide (Tukey 
Krammer multiple comparison tests) 
Mean incision wound breaking strength on 11th
 
 post wounding 
day was significantly higher in amlodipine and glibenclamide 
groups as compared to control group. In the enalapril group, the 
mean incision wound breaking strength was numerically higher 
than the diabetic control group. However, it did not reach 
predefined statistical significance (table 2). Granulation tissue 
dry weight for enalapril and glibenclamide groups was 
significantly higher than the control group. There was no 
statistically significant difference in hydroxyproline contents 
among all the four groups (table 2). 
Table 2: Effect of amlodipine and enalapril on incision and dead space wound model 
S. 
No. 
Group Incision wound breaking 
strength (gm) 
Granulation tissue dry weight (mg/100 
gm body weight) 




265.8±10.4 26.1±0.6 19.3±0.5 
2 Glibenclamide 369.2±8.9* 37.5±0.9* 24.4±0.9 
3 Amlodipine 337.5±17.1* 29.6±1.2 23.6±0.7 
4 Enalapril 310.8±9.9 30.9±1.1* 22.6±1.4 
n=6 in each group, values are represented as mean±SEM. * P<0.05 as compared to diabetic control. (Tukey-Krammer multiple comparison tests) 
A semi-quantitative histological analysis of 11th post-wounding day granulation tissue did not show any difference in any of the parameters 
examined (table 3). 
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Arrows on day 11, shows epithelization 
Fig. 1: The excision wound healing time course noted on 0, 3, 7 and 11 post-operative day 
 
Table 3: Semi-quantitative evaluation of histological changes in granulation tissue in dead space wound model 
Histological change Groups 
Diabetic control Glibenclamide Amlodipine Enalapril 
Neutrophils 1.0±0.36 1.5±0.55 1.3±0.21 1.5±0.56 
Macrophages 0.3±0.21 0.8±0.3 0.8±0.16 0.2±0.16 
Fibroblasts 2.5±0.42 1.4±0.2 1.6±0.21 3±0.63 
Neo-angiogenesis 1.8±0.54 1.2±0.16 1.5±0.56 1.1±0.23 
n=6 in each group, values are represented as mean±SEMs. (Dunn multiple comparison test, P<0.05) 
 
 
Fig. 2: Wound healing curve. The graph shows percentage of 
excision wound closure over time period 
 
DISCUSSION 
This study evaluated wound healing activity of amlodipine, and 
enalapril in diabetic Wistar rats based on previous observations that 
amlodipine increases endothelial NO bioavailability, and enalapril 
promotes angiogenesis [8, 10-12]. Angiogenesis and endothelial NO 
play an important role in enhancing wound healing, especially in 
diabetic wound healing, where they are negatively affected [6, 9]. NO 
promotes angiogenesis in addition to its other wound healing 
promoting properties [22]. Furthermore, topical NO donor, glyceryl 
trinitrate, has been demonstrated to promote wound healing in 
diabetic Wistar rats [7]. Amlodipine and enalapril have been 
studied for wound healing activity in non-diabetic wounds, 
however, at the best of our knowledge; present study is the first to 
evaluate wound healing activity of amlodipine, and enalapril in 
diabetic wounds [13-15]. 
In the present study, STZ-induced diabetes model was used, which is 
well-established model to study diabetic wound healing [23]. STZ-
induced diabetes model has been shown to exhibit decreased 
cutaneous endothelial nitric oxide synthase (eNOS) expression, 
constitutive NOS activity, and increased superoxide levels [24]. 
Furthermore, it has been demonstrated that in STZ-induced 
diabetes, angiogenesis is impaired. [25] Thus, STZ-induced diabetes 
model provides suitable opportunity to study effects of present 
study agents on diabetic wound healing. Glibenclamide was used as 
active control as it has been demonstrated that lowering of blood 
glucose in diabetes helps to promote wound healing [26]. This active 
control group helps differentiate if the study agents have any 
additional advantage in promoting diabetic wound healing over 
blood glucose lowering agents that could promote wound healing by 
merely improving glucose homeostasis in diabetes.  
In the present study, at day 11, re-epithelialization in the excision 
wound model was significantly higher in both the treatment groups 
Hirapara et al. 
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as compared to diabetic and active control groups. Wound 
contraction, on 11th
NO treatment has been observed to promote re-epithelialization in 
healing wounds [7, 27]. Another report suggests that inducible nitric 
oxide synthase (iNOS) inhibitor N
 post wounding day, in both treatment groups 
was observed non-significantly higher than diabetic control, and 
active control group. In a previous study of dexamethasone 
suppressed wound healing, amlodipine enhanced rate of wound 
contraction and re-epithelialization [13]. Another study showed that 
enalapril improves wound healing by enhancing re-epithelialization, 
wound breaking strength, and granulation tissue collagen content 
[15]. In accordance with observations in the previous studies, in the 
present study, amlodipine and enalapril increased re-epithelisation 
in the diabetic wound. However, in contrast to previous studies, in 
present study amlodipine and enalapril did not enhance wound 
contraction. This contradictory observation can be possibly 
explained by the fact that wound contraction is already hampered in 
diabetes and as a result wound contraction promoting the effect of 
study agents could not reach statistical significance. The re-
epithelialization enhancing the effect of amlodipine is plausibly 
brought about by its effect on NO bioavailability. Amlodipine has 
been shown to enhance NO production from endothelium and 
prolong its half-life and thereby increase NO bioavailability [8].  
ω
Both amlodipine and enalapril significantly increased re-
epithelisation in excision wound compared to glibenclamide. This 
observation suggests that amlodipine and enalapril have an 
additional advantage in terms of increased re-epithelialization over 
merely blood glucose lowering agents. In human, the skin over the 
foot, which is commonly involved in the diabetic wound, is 
stretched and closely tethered to the dermis. It heals 
predominantly by re-epithelialization due to lack of loose areolar 
tissue. Thus, enalapril and amlodipine may help to enhance wound 
healing in the diabetic foot.  
-imino ethyl L-lysine (L-NIL) 
decreases proliferation of keratinocytes and delays re-
epithelialization with atrophied hyperproliferative epithelium at the 
wound edge [28, 29]. The re-epithelialization enhancing effect of 
enalapril is plausibly explained by its angiogenesis stimulating 
property. The angiogenesis stimulating property of ACE inhibitors is 
patented with US Patent No. 6,191,144 B1, 2001. [10] Diabetes is 
known to affect the angiogenesis process negatively by decreasing 
serum NO and vascular endothelial growth factor (VEGF) 
concentration. Enalapril has been shown to increase serum NO and 
VEGF levels in diabetic rats [12]. High level of VEGF mRNA was 
found in keratinocytes present in wound surface [30]. In addition to 
stimulating angiogenesis, VEGF has also been found to accelerate 
epithelialization in the wound healing process [31-33].  
In incision wound model, amlodipine significantly increased incision 
wound breaking strength compared to diabetic control. Calcium 
channel blockers (CCBs), including the amlodipine, are considered 
potential etiological factor for drug-induced gum hypertrophy [34, 
35]. The hallmark of gum hypertrophy is increased amount of 
connective tissue dominated by collagen fibers [36]. Underlying 
proposed mechanism are up-regulation of cytokines like 
transforming growth factor β1 (TGF β1), and interleukin-6 (IL6), 
which increase the synthesis and reduce the proteolytic activities of 
fibroblasts, the source of collagen [35, 37-39].  
Glibenclamide also significantly increased incision wound strength 
compared to diabetic control; however, there was no significant 
difference in incision wound breaking strength between amlodipine 
and glibenclamide. This observation suggests that amlodipine has a 
similar magnitude of effect in increasing incision wound breaking 
strength as could be achieved by glucose lowering agents in 
diabetes. Enalapril did not have any significant effect on incision 
wound breaking strength compared to diabetic control. During first 
three weeks of wound healing, the wound strength correlates with 
scar collagen content, while in the late phase, organized 
(architecturally rearranged) collagen contributes to increased 
wound strength [40]. In experimental models, enalapril treatment 
has been shown to reduce collagen deposition in rat heart ventricles 
or large/small arteries, which explain the non-significant effect of 
enalapril on wound breaking strength [41]. 
In dead space wound model, enalapril significantly increased dry 
granulation tissue weight as compared to diabetic control; however, 
amlodipine did not have a significant effect on dry granulation tissue 
weight. Angiogenesis supports growth and contents of granulation 
tissue components and thereby improves granulation tissue weight 
in enalapril group [15, 42]. There was no significant difference in 
hydroxyproline content among all the groups. In the present study, 
the colorimetric technique was used to measure hydroxyproline 
content in granulation tissue, which is less sensitive, and may have 
missed minute differences in hydroxyproline content between 
groups. 
Histological examination of granulation tissue did not reveal any 
significant difference among the groups in polymorph nuclear cell 
infiltration, macrophage, fibroblast, or neo-angiogenesis in this 
particular study setup. 
The limitations of this study are that the methods used in 
quantifying re-epithelialization, and hydroxyproline estimation are 
less sensitive. Furthermore, for evaluation of angiogenesis in 
granulation tissue, specific immunostaining using a blood vessel 
marker such as CD31 would have been more revealing. However, 
due to unavailability of resources, such specific immunostaining 
could not be performed.  
CONCLUSION 
This study demonstrates that amlodipine and enalapril enhance the 
re-epithelialization in the diabetic wound. In addition, amlodipine 
increases wound tensile strength while enalapril increases 
granulation tissue formation in diabetic wounds. Hypertension is a 
common co-morbidity in patients of diabetes, and amlodipine and 
enalapril are commonly used anti-hypertensive agents. Choosing 
amlodipine or enalapril as antihypertensive in such diabetic patients 
may help to improve impaired wound healing in these patients. 
Further human trials are warranted to demonstrate similar benefits 
in improving impaired wound healing in patients of diabetes. 
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